

3-Year Healthcare Resource Consumptions of Patients with Immunoglobulin A Nephropathy in a Large Real-World Italian Database



ISPOR Europe 2024 17-20 November 2024 Barcelona, Spain

Silvia Calabria¹, Giulia Ronconi¹, Letizia Dondi¹, Leonardo Dondi¹, Irene Dell'Anno¹, Carlo Piccinni¹, Immacolata Esposito², Alice Addesi², Luigi Biancone³, Gaetano La Manna⁴, Nello Martini¹

1. Fondazione ReS (Ricerca e Salute) – Research and Health Foundation, Roma, Italy; 2. Drugs & Health Srl, Roma, Italy; 3. Città Della Salute e Della Scienza Hospital and University of Turin, Italy; 4. IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy

Immunoglobulin A Nephropathy (IgAN) is a rare disease, and the most common primary glomerulonephritis worldwide. IgAN is poorly described in real-world settings, although real-world data have been validated as reliable in identifying and characterizing patients with rare diseases.

-> AIMS: To assess the 3-year healthcare resource consumptions reimbursed by the Italian Health Service (Servizio Sanitario Nazionale - SSN) for patients with a new in-hospital diagnosis of IgAN.

Retrospective observational and longitudinal cohort study through the administrative healthcare database of Fondazione Ricerca e Salute (ReS)

Identification criteria


Index date

Follow-up analyses

primary/secondary diagnosis of In-hospital glomerulonephritis (ICD9-CM codes) AND renal biopsy procedures (ICD9-CM codes) in the same hospital discharge form (HDF).


Excluded patients with:

- in-hospital diagnosis codes identifying other nephropathies during the 12 months following index date;
- same identification criteria (to identify incident patients) or supplied with insulin (as indicator of diabetic nephritis) during the previous period.




Free filled dispensations of **drugs** recommended for IgAN (i.e., angiotensin converting enzyme inhibitors, systemic corticosteroids, angiotensin II receptor blockers, immunosuppressants) and **other** drugs;

- **Kidney replacement therapy (KRT)**, i.e., kidney transplantation and dialysis;
- Hospitalizations;
- **Emergency Department** (ED) accesses;
- Local outpatient specialist care;
- **Direct costs** charged to the SSN



	is with in-nospital primary/secondary diagnosis of igan (1,429)
3rd year (AND with in-hospital renal biopsy procedure (367)
	Patients with new in-hospital diagnosis of IgAN: 363
	excl. patients with the same criteria during the look-back period)
Kidney Rep	Iding patients with diagnosis of other nephropathies during 12-month
≥1∤	follow-up (n=53), and supplied with insulin (n=18)
Hemodialysis	
Peritoneal dialy	
Kidney transpla	
≥1 k	population of patients with new in-hospital diagnosis of IgAN:
Hemodialysis	292 (annual incidence: 1.25 / 100,000 inhabitants)
Peritoneal dialy	Females: 35.6%; Median age (Q1;Q3): 41 (27; 57)
Kidney transpla	
≥11	≥ 1 comorbidity: 68.2%
Hemodialysis	
Peritoneal dialy	
Kidney transpla	



healthcare resources reimbursed by the SSN due to hospitalizations, supplies of drugs for IgAN and comorbidities, which has also contributed to a high economic impact on the SSN. These findings are useful to estimate the possible clinical and economic benefits from an early taking charge of patients with IgAN, i.e., the reduction of risk of disease progression and need for

Conflict of interest: Calabria S is an employee of Fondazione ReS.

Funding: CSL Vifor (Glattbrugg, Switzerland) provided funding and input to this study design.

Scan and download the poster!